Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: A report of two cases

British Journal of Dermatology

Volumn 169, Issue 1, 2013, Pages 172-176

  Green, J S ^a   Norris, D A ^a,b   Wisell, J ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBINTERFERON ALPHA2B; CARMUSTINE; CISPLATIN; CORTICOSTEROID; DABRAFENIB; DACARBAZINE; TRAMETINIB; ANTINEOPLASTIC AGENT; B RAF KINASE; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; OXIME; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CASE REPORT; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG STABILITY; FEMALE; GAMMA KNIFE RADIOSURGERY; GRANULOMATOUS INFLAMMATION; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MALE; MELANOMA; METASTATIC MELANOMA; NEVUS; PAPULAR RASH; PRIORITY JOURNAL; PUNCH BIOPSY; RASH; SENTINEL LYMPH NODE BIOPSY; TOPICAL TREATMENT; TUMOR BIOPSY; AGED; ANTAGONISTS AND INHIBITORS; GENETICS; HEAD AND NECK NEOPLASMS; METASTASIS; MIDDLE AGED; MUTATION; SCALP; SKIN NEOPLASMS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMIDAZOLES; MALE; MAP KINASE KINASE KINASES; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SCALP; SKIN NEOPLASMS;

EID: 84879922967     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12279     Document Type: Article

References (28)

1. Balch C, Gershenwald J, Soong S, et al,. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 199-206.
2. Chapman P, Hauschild A, Robert C, et al,. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
3. Sosman J, Kim K, Schuchter L, et al,. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-14.
4. Spagnolo F, Queirolo P,. Upcoming strategies for the treatment of metastatic melanoma. Arch Dermatol Res 2012; 304: 177-84.
5. Lacouture ME, Reilly LM, Gerami P, Guitart J,. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008; 19: 1955-61.
6. Chu EY, Wanat KA, Miller CJ, et al,. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol 2012; 67: 1265-72.
7. Zimmer L, Hillen U, Livingstone E, et al,. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012; 30: 2375-83.
8. Kong HH, Cowen EW, Azad NS, et al,. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007; 56: 171-2.
9. Kong H, Sibaud V, Chanco Turner M, et al,. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol 2008; 144: 820-2.
10. Hong D, Reddy S, Prieto V, et al,. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol 2008; 144: 779-82.
11. Huang V, Hepper D, Anadkat M, et al,. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol 2012; 148: 628-33.
12. Boyd K, Vincent B, Andea A, et al,. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma. J Am Acad Dermatol 2012; 67: 1375-9.
13. Balagula Y, Huston K, Busam K, et al,. Dermatologic side effects with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs 2011; 29: 1114-21.
14. Schad K, Baumann Conzett K, Zipser M, et al,. Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 2010; 16: 1058-964.
15. Oberholzer P, Kee D, Dziunycz P, et al,. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30: 316-21.
16. Hatzivassiliou G, Song K, Yen B, et al,. RAF inhibitors prime wild type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-5.
17. Pollock P, Harper U, Hansen K, et al,. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33: 19-20.
18. Sekulic A, Colgan MB, Davis MD, et al,. Activating BRAF mutations in eruptive melanocytic naevi. Br J Dermatol 2010; 163: 1095-8.
19. Bauer J, Curtin J, Pinkel D, et al,. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol 2007; 127: 179-82.
20. Denianke K, Gottlieb G,. Granulomatous inflammation in nevi undergoing regression (halo phenomenon): a report of six cases. Am J Dermatopathol 2008; 30: 233-5.
21. V600E inhibitor, displays potent antitumor activity in preclinical melanoma models Cancer Res 2010; 70:5518-27. Erratum in: Cancer Res 2010; 70: 9527.
22. Hauschild A, Grob J, Demidov L, et al,. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 28: 358-65.
23. Bergman W, Willemze R, De Graaff-Reitsma C, et al,. Analysis of major histocompatibility antigens and the mononuclear cell infiltrate in halo nevi. J Invest Dermatol 1985; 85: 25-9.
24. Akasu R, From L, Kahn H,. Characterization of the mononuclear infiltrate involved in regression of halo nevi. J Cutan Pathol 1994; 21: 302-11.
25. Copeman P, Lewis M, Phillips T, et al,. Immunological associations of the halo nevus with cutaneous malignant melanoma. Br J Dermatol 1973; 88: 127-37.
26. Autier J, Escudier B, Wechsler J, et al,. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008; 144: 886-92.
27. Hurst E, Mauro T,. Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature. Arch Dermatol 2005; 141: 865-8.
28. Heinzerling L, Anliker M, Muller J, et al,. Sarcoidosis induced by interferon-α in melanoma patients: incidence, clinical manifestations, and management strategies. J Immunother 2010; 33: 834-9.